Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

lunresertib (Debio2513)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Debiopharm, Repare Therap

Drug class:

PKMYT1 inhibitor

Related drugs:

‹

›

CCNE1 amplification	Solid Tumor	CCNE1 amplification	Solid Tumor	Debio2513 Sensitive: C2 – Inclusion Criteria Debio2513 Sensitive : C2	Debio2513 Sensitive: C2 – Inclusion Criteria Debio2513 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	Debio2513 Sensitive: C2 – Inclusion Criteria Debio2513 Sensitive : C2	Debio2513 Sensitive: C2 – Inclusion Criteria Debio2513 Sensitive : C2
FBXW7 mutation	Solid Tumor	FBXW7 mutation	Solid Tumor	Debio2513 Sensitive: D – Preclinical Debio2513 Sensitive : D	Debio2513 Sensitive: D – Preclinical Debio2513 Sensitive : D
CCNE1 amplification	Hepatocellular Cancer	CCNE1 amplification	Hepatocellular Cancer	Debio2513 Sensitive: D – Preclinical Debio2513 Sensitive : D	Debio2513 Sensitive: D – Preclinical Debio2513 Sensitive : D